Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Palliative care in heart, lung, renal and neurological disease

Palliative and end-of-life care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Acute organ-failure deterioration

Advanced chronic disease can still produce reversible pulmonary oedema, infection, bronchospasm, electrolyte disturbance, seizure or device shock. A palliative plan should accelerate proportionate relief, not replace acute assessment automatically.

Action: Use ABCDE care, identify the dominant mechanism and check the emergency plan and current capacity. Treat hypoxaemia, congestion, bronchospasm, sepsis, hyperkalaemia or seizure under the appropriate pathway when consistent with goals; involve the relevant specialty and palliative team and provide opioid or anxiolytic symptom relief without delaying reversible treatment.

Synopsis

Integrate palliative care early with active treatment for advanced cardiac, respiratory, kidney and neurological disease, managing symptom mechanisms, uncertain trajectories, treatment withdrawal and organ-specific medicine risks without relying on a cancer model.

  • Palliative care is based on need, not diagnosis or a precise prognosis, and should run alongside disease-modifying heart, lung, kidney and neurological treatment.
  • First-line assessment separates the symptom mechanism from the disease label: congestion, bronchospasm, hypoxaemia, uraemia, weakness, dysphagia, anxiety and deconditioning require different responses.
  • Organ failure often fluctuates through crises and partial recovery; discuss uncertainty and use repeated trigger-based planning rather than waiting for a predicted final week.
  • In heart failure, optimise congestion and guideline-directed treatment while tolerated, review hypotension and kidney injury and discuss implantable-defibrillator shock deactivation before dying.
  • In advanced lung disease, maximise inhaled treatment, rehabilitation and breathing techniques; use oxygen for qualifying hypoxaemia and consider low-dose opioid for refractory breathlessness after assessment.
  • In advanced kidney disease, offer shared choice between dialysis, conservative kidney management and time-limited dialysis, integrating symptom and future-care planning whichever route is chosen.
  • Severe renal impairment increases accumulation of morphine, codeine, gabapentinoids and several sedatives; choose and dose symptom medicines with renal and palliative expertise.
  • Neurological disease requires early communication support, swallow and secretion planning, equipment, caregiver review and discussion of ventilation, gastrostomy and treatment withdrawal while the person can participate.
  • Continue essential Parkinson and antiseizure treatment through a feasible route; abrupt withdrawal can cause life-threatening deterioration mistaken for dying.
  • A decision to stop dialysis or assisted ventilation requires capacity or best-interests assessment, anticipatory symptom treatment and continuity of care; it is withdrawal of a burdensome treatment, not assisted dying.

Key red flags

New chest pain, syncope, shock or recurrent implantable-defibrillator shocks requires urgent cardiac and device assessment.

Silent chest, exhaustion, severe hypoxaemia, hypercapnic drowsiness or stridor indicates respiratory emergency.

Hyperkalaemic ECG change, severe fluid overload, uraemic pericarditis or encephalopathy needs immediate renal decision-making.

New choking, weak cough, aspiration or inability to manage secretions requires urgent airway and swallow review.

Abrupt cessation of levodopa, baclofen, corticosteroid or antiseizure treatment can cause dangerous withdrawal syndromes.

Increasing sedation, myoclonus or hallucinations after renal decline suggests medicine accumulation.

Stopping dialysis or ventilation without an agreed symptom, location and after-hours plan risks severe avoidable distress.

Acute reversible crisis

Pulmonary oedema, severe exacerbation, sepsis, hyperkalaemia, prolonged seizure, aspiration or ventilatory failure requires immediate assessment within the agreed treatment ceiling.

Investigation priorities

01
First-line symptom-mechanism assessmentFirst stepFirst line

Define breathlessness, fluid, pain, fatigue, cognition, swallow, secretion, mobility and treatment adherence against the recent baseline.

Management branches

Parallel careOptimise disease treatment and palliation together

Advanced organ or neurological disease causes persistent symptoms, recurrent admissions or functional decline.

  1. Identify treatable symptom mechanisms and optimise specialist therapy, rehabilitation, equipment and self-management within tolerance and goals.
  2. Introduce palliative support for refractory symptoms, communication, family needs and future planning without requiring cessation of disease treatment.
  3. Agree patient-valued outcomes and reassess after each crisis, documenting which active treatments remain proportionate.

Key medicines

Low-dose morphine trial for refractory breathlessnessFor an opioid-naive adult after optimal disease treatment, a common Scottish palliative starting regimen is immediate-release oral morphine 2 mg as needed, initially no more often than every four hours, with early review before regular dosing.Use a lower or alternative plan in frailty, hypercapnic vulnerability or kidney failure; monitor alertness, respiratory rate, nausea and constipation and never substitute it for emergency treatment.
Loop diuretic for symptomatic congestionContinue or adjust the person's established oral or intravenous loop-diuretic regimen to weight, oedema, blood pressure, renal function and response; use specialist home parenteral protocols where commissioned rather than an unmonitored standard dose.Monitor hypotension, dehydration, kidney injury, sodium, potassium and access burden; apparent renal worsening may require expert interpretation rather than automatic cessation during effective decongestion.
Open full textbook →Answer 2 questions
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG106 chronic heart failureSymptom assessment, medicines, monitoring, multidisciplinary care and palliative referral in heart failure.
  • NICE NG115 chronic obstructive pulmonary diseaseOptimised COPD care, oxygen assessment, pulmonary rehabilitation and refractory breathlessness palliation.
  • NICE NG203 chronic kidney diseaseShared decisions, renal replacement, conservative management, symptom burden and medicine safety.
  • NICE NG42 motor neurone diseaseCommunication, nutrition, secretion, ventilation, advance planning and multidisciplinary neurological care.
  • Scottish Palliative Care Guidelines breathlessnessNon-drug measures, oxygen, opioid dosing and review for persistent breathlessness.
  • GMC end-of-life treatment decisionsCapacity, refusal, withdrawal of life-sustaining treatment and continuity of symptom care.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

Content changes
Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom